Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Trending Now
Inflammasome Therapeutics’ Kamuvudine K8 Reduces Geographic Atrophy Lesion Growth by 54% in Phase 2 Study
GenSight Biologics Publishes GS030 PIONEER Optogenetic Therapy Results in the New England Journal of Medicine
Ophthalmology Industry Consolidation Accelerates as MyEyeDr and Glaukos Announce Strategic Deals
Breaking News
Surgical innovation in dry eye disease: Salivary gland transplant
Ağustos 27, 2025
Next-generation IOLs advance complex cataract care
Ağustos 26, 2025
OCT changes with low-level red light therapy for myopia in children
Ağustos 26, 2025
Alcon presenting at APACRS 2025
Ağustos 21, 2025
Breaking News
Popular Now
AAO 2026 Highlights Hospital Ophthalmology Coverage Gaps and Growing Reimbursement Pressures
Access to hospital-based eye care and reimbursement were policy topics at the…
Inflammasome Therapeutics’ Kamuvudine K8 Reduces Geographic Atrophy Lesion Growth by 54% in Phase 2 Study
Phase 2 data for kamuvudine K8, an investigational inflammasome-directed treatment from Inflammasome…
Ophthalmology Industry Consolidation Accelerates as MyEyeDr and Glaukos Announce Strategic Deals
Two transactions announced in September and October 2026 show capital moving through…
GenSight Biologics Publishes GS030 PIONEER Optogenetic Therapy Results in the New England Journal of Medicine
GenSight Biologics and the Quinze-Vingts National Ophthalmology Hospital in Paris announced on…
Collaborate With Us
Join forces with Ophthalmology News to reach a global community of eye care professionals. Whether you want to contribute an article, share research, or explore partnership opportunities, we’d love to hear from you.
Editor Choice
Dompé enrolls first patients in phase 3 study of isocyclosporin for treatment of atopic keratoconjunctivitis | Ophthalmology Times
(Image Credit: AdobeStock/kerkezz) Biopharmaceutical company Dompé has enrolled the first patients in…
Seeing the difference: Multimodal imaging for AMD and GA | Ophthalmology Times
(Image Credit: AdobeStock/jtamm) A timely and accurate diagnosis of retinal disease gives…
NCX 470 advances toward US, China NDA submissions for NCX 470 | Ophthalmology Times
(Image Credit: AdobeStock) Nicox has announced it has acquired and analyzed all…
Unmet Needs in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained…
Management and Monitoring Strategies in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained…
Spotlight on women’s health: Understanding thyroid eye disease | Ophthalmology Times
Image by Jennifer Toomey/MJH Life Sciences using AI Thyroid eye disease (TED),…
Malar edema: Perspectives from plastic surgery and ophthalmology | Ophthalmology Times
(Image Credit: AdobeStock/Alessandro Grandini) Malar edema, the collection of fluid below the…
FDA extends Aldeyra’s reproxalap PDUFA after requesting additional clinical study report | Ophthalmology Times
(Image Credit: AdobeStock) The US Food and Drug Administration (FDA) has extended…
Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases | Ophthalmology Times
This discussion centers on real-world comparisons between aflibercept 2 mg and the…
Worth Reading
Meeting expectations with evolving technology
Ağustos 26, 2025
/ Patient Education, Research & Studies, Technology & Innovation, Treatments & Surgery
Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
Ağustos 26, 2025
/ Industry News, Patient Education, Research & Studies, Treatments & Surgery
Possible protective role of cannabis in preventing postoperative proliferative vitreoretinopathy after retinal detachment repair
Ağustos 26, 2025
/ Patient Education, Research & Studies
Next-generation IOLs advance complex cataract care
Ağustos 26, 2025
/ Patient Education, Research & Studies, Treatments & Surgery
Subscribe Now
Enter your email address below and subscribe to our newsletter